High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa
Treatment success rates of rifampicin resistant (RR)/multi-drug resistant (MDR) tuberculosis
(TB) in South Africa range from 43±48%, falling short of the World Health Organization’s
target of 75%. We present rates and assess predictors of attrition by 12 months on
treatment.Prospective observational cohort analysis of adults (18 years) initiating RR/MDR-TB treatment
Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa
We retrospectively matched adult patients diagnosed with laboratory-confirmed RR-TB in Johannesburg
from 07/2011–06/2012 (early cohort) and 07/2013–06/2014 (late cohort) with records of patients initiating DR-TB
treatment at one of the city’s four public sector treatment sites. We determine the proportion of persons diagnosed
with RR-TB who initiated DR-TB treatment and report time ...
Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes
The World Health Organization recommends that antiretroviral therapy (ART) programs in resource-limited settings develop third-line ART policies. South Africa developed a national third-line ART program for patients who have failed both first-line non-nucleoside reverse transcriptase inhibitor–based ART and second-line protease inhibitor (PI)-based ART. We report on this program.
HE2RO has been awarded a new 5-year Co-operative Agreement from USAID. This new program, the HIV/AIDS Economics and Research Activity, called EVIDENCE will run...
HE2RO has been approved to be a HBNU site for the Fogarty Global Health Training Program. The program provides opportunities to generate a new...
HE2RO and BU are pleased to announce a new project focusing on differentiated models of HIV treatment delivery: AMBIT.